CAR-T cell therapy has spread into earlier lines of care over the last ten years, going beyond heavily pretreated populations ...
A personalized therapy involving re-engineered cells has brought phenomenal results for a woman with a rare trio of ...
A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, ...
A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...
In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement ...
Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...
Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana is offering a CAR-T cell-based immunotherapy, which genetically ...
The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen ...
Once built to fight cancer, CAR‑T therapy is now offering new hope for patients with severe autoimmune disease.
A woman with three different autoimmune conditions had all of them treated simultaneously by genetically modifying her immune ...